[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymph-node-involvement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymph-node-involvement":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100578334","phase-2-feasibility-of-fluorescence-imaging-with-bevacizumab-800cw-during-bronchoscopy-100578334",false,"NCT06809946","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I","DEFLECT I","Inclusion Criteria:\n\n1. Signed informed consent prior to participation in the study.\n2. Age ≥ 18 years.\n3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).\n4. Patient is considered fit to undergo a diagnostic and\u002For therapeutic bronchoscopy (with or without addition of virtual navigation and\u002For endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.\n\nExclusion Criteria:\n\n1. History of infusion reactions to bevacizumab.\n2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n3. Pregnancy or breast feeding.","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and\u002For lymph nodes considered to be malignant.",[27,28,29,30],"Lung Neoplasms","Pulmonary Neoplasms","Lymph Node Involvement","Pulmonary Nodule",[32,33,34,35,36],"Fluorescence molecular bronchoscopy","Bevacizumab-800CW","Near-infrared fluorescence imaging","Molecular imaging","Pulmonary nodule","NOT_YET_RECRUITING","2026-03-24",{"date":40,"type":41},"2026-03-30","ACTUAL",{"date":43,"type":21},"2026-08-17",{"date":45,"type":21},"2028-08-17",{"name":47,"class":48},"University Medical Center Groningen","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100597853","phase-2-a-prospective-phase-ii-study-of-postoperative-concurrent-chemoradiotherapy-in-patients-with-intrahepatic-cholangiocarcinoma-100597853","NCT07063888","A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma","A Prospective Phase II Study of Adjuvant Concurrent Chemoradiotherapy With Simultaneous Integrated Boost Following Hepatectomy for Intrahepatic Cholangiocarcinoma With Narrow Margin or Nodal Involvement","Inclusion Criteria:\n\n* Age \\> 18 years, \\\u003C 80 years\n* Patients with primary surgical treatment\n* Postoperative pathology confirmed intrahepatic cholangiocarcinoma\n* Postoperative pathology showing narrow resection margin (\\\u003C1cm) or positive lymph nodes\n* R0\u002FR1 resection\n* Postoperative Child-Pugh score A5-B7\n* Patients meeting either of the following conditions must undergo preoperative or pre-radiotherapy PET-CT to exclude distant metastasis or lymph node metastasis beyond the region from the lower esophagus to the aortic bifurcation\n\n  1. Lymph node metastasis accounting for \\>50% of dissected nodes\n  2. Lymph node metastasis involving the paracardial region or below the renal vein level\n* Postoperative contrast-enhanced liver MRI to exclude Intrahepatic satellite nodules\n* Recovery from surgery with Eastern Cooperative Oncology Group performance status score of 0-2\n* Estimated life expectancy \\>3 months\n\nExclusion Criteria:\n\n* History of malignancies, except for basal cell skin carcinoma and in situ carcinoma of the cervix\n* Had prior abdominal irradiation\n* Had prior liver transplantation\n* Had serious myocardial disease or renal failure\n* Had moderate or severe ascites with obvious symptoms 4 months after surgery\n* Duration from surgery ≥ 4 months","80 Years",{"count":59,"type":21},66,[24],"This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant concurrent chemoradiotherapy with simultaneous integrated boost following hepatectomy for intrahepatic cholangiocarcinoma with narrow margin (\\\u003C1cm) or nodal involvement. Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg\u002Fm² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg\u002Fm² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative. The primary endpoint is 2-year recurrence-free survival. The secondary endpoints are 2-year overall survival, local-regional control rate and incidence of grade 3 or higher adverse events.",[63,64,65,29],"Intrahepatic Cholangiocarcinoma (Icc)","Adjuvant Chemoradiotherapy","Narrow Margin","RECRUITING","2025-07-11",{"date":69,"type":41},"2025-07-14",{"date":71,"type":41},"2025-05-16",{"date":73,"type":21},"2028-05-15",{"name":75,"class":48},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]